Risk Factor Driven Upstream Therapy in Early Atrial Fibrillation

The Routine versus Aggressive upstream rhythm control for prevention of Early persistent atrial fibrillation in heart failure study

Michiel Rienstra, Anne H. Hobbelt, Marco Alings, Jan G.P. Tijssen, Marcelle D. Smit, Johan Brügemann, Bastiaan Geelhoed, Robert G. Tieleman, Hans L. Hillege, Raymond Tukkie, Dirk J. Van Veldhuisen, Harry J.G.M. Crijns, Isabelle C. Van Gelder, for the RACE 3 Investigators
Background

- Maintenance of sinus rhythm improves AF-related symptoms

- However, maintenance of sinus rhythm is cumbersome due to atrial remodelling, caused by risk factors and diseases underlying AF, and AF itself

- Recognition of the consequences of atrial remodelling has led to the notion that early intervening may prevent AF progression

- Risk factor driven upstream therapy refers to interventions that aim to modify the atrial substrate, and has a favourable effect on risk factors and diseases underlying AF
Hypothesis and trial design

- **Hypothesis:**
  Risk factor driven upstream therapy is superior to conventional therapy for maintenance of sinus rhythm in patients with early persistent AF and HF

- **RACE 3 trial design:**
  - Prospective, randomized, open label, superiority trial
  - Investigator-initiated
  - Multicenter: 14 sites in The Netherlands and 3 in United Kingdom
  - Enrolment between 2009 and 2015
  - 1 year follow-up
Upstream therapy consists of:
1) Mineralocorticoid receptor antagonist
2) Statin
3) ACE-inhibitors and/or angiotensin-receptor blockers
4) Cardiac rehabilitation:
   - physical activity
   - dietary restrictions
Primary endpoint

Sinus rhythm at 1-year

Upstream: 75%
Conventional: 63%

Odds ratio: 1.765
Lower 95% confidence limit: 1.115

Superiority hypothesis was proven (p=0.021)
Conclusion and implication

- The RACE 3 study shows that risk factor driven upstream therapy, including treatment of risk factors and change of lifestyle, is effective and feasible to improve maintenance of sinus rhythm in patients with early persistent AF and HF.

- The effect of upstream therapy on reduction of risk factors and cardiovascular diseases, instead of atrial remodeling, was favourable.
RACE 3 study organisation

Steering committee
I.C. Van Gelder
H.J.G.M. Crijns
M. Alings
M. Rienstra
J.G.P. Tijssen
M.D. Smit
J. Brügemann
R.G. Tieleman
H.L. Hillege
R. Tukkie
D.J. Van Veldhuisen

Trial and data management
W.J.M. Mol, O. Eriks

Central Holter core lab
J. Haaksma

Secondary end point adjudication committee
R.A. Tio, J.P. Van Melle

Statistical analysis committee
M. Rienstra, B. Geelhoed, H.L. Hillege, J.G.P. Tijssen, I.C. Van Gelder

Data Safety and Monitoring Board
H.J.J. Wellens, A.M. Wilde, Y.M. Pinto

Supported by:
Netherlands Heart Foundation
Netherlands Heart Institute
RACE 3 investigators

The Netherlands:
University Medical Center Groningen, Groningen - I.C. Van Gelder
Amphia Hospital, Breda - M. Alings
Martini Hospital, Groningen - R.G. Tieleman
Admiraal De Ruyter Hospital, Goes - I. Aksoy
Ziekenhuisgroep Twente Location Almelo, Almelo, - G.C.M. Linssen
Rijnstate Hospital, Arnhem - H.A. Bosker
Spaarne Hospital, Haarlem - G.J.E. Verdel
Radboud University Nijmegen Medical Center, Nijmegen - E. Cramer
Maastricht University Medical Center, Maastricht - H.J.G.M. Crijns
Tergooi Hospital, Blaricum - R.H.J. Peters
Deventer Hospital, Deventer - Y.S. Tuininga
Ommelander Hospital Group, Winschoten/Delfzijl, - A. Van Der Galiën/V. Hagens
Onze Lieve Vrouwe Gasthuis, Amsterdam - G.S. De Ruiter

United Kingdom:
Birmingham City Hospital, Birmingham - G.Y.H. Lip
Leeds General Infirmary, Leeds - M. Tayebjee
Poole Hospital, Poole - C. Boos